S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, disrupting traffic in the global waterway
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, disrupting traffic in the global waterway
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, disrupting traffic in the global waterway
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, disrupting traffic in the global waterway
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
NASDAQ:DVAX

Dynavax Technologies (DVAX) Stock Forecast, Price & News

$11.66
+0.18 (+1.57%)
(As of 06/2/2023 ET)
Compare
Today's Range
$11.48
$11.70
50-Day Range
$9.65
$11.66
52-Week Range
$9.42
$17.48
Volume
1.07 million shs
Average Volume
1.16 million shs
Market Capitalization
$1.49 billion
P/E Ratio
7.47
Dividend Yield
N/A
Price Target
$24.00

Dynavax Technologies MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
105.8% Upside
$24.00 Price Target
Short Interest
Bearish
14.38% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.59
Upright™ Environmental Score
News Sentiment
1.42mentions of Dynavax Technologies in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$190,914 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.56) to ($0.24) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.44 out of 5 stars

Medical Sector

157th out of 983 stocks

Pharmaceutical Preparations Industry

69th out of 486 stocks


DVAX stock logo

About Dynavax Technologies (NASDAQ:DVAX) Stock

Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Receive DVAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dynavax Technologies and its competitors with MarketBeat's FREE daily newsletter.

DVAX Stock News Headlines

Dynavax to Present at Upcoming Investor Conferences
Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
The Latest Analyst Ratings for Dynavax Technologies
Q1 2023 Dynavax Technologies Corp Earnings Call
Dynavax Technologies: The Covid Lifeline Expires
Dynavax Technologies earnings: here's what to expect
See More Headlines

DVAX Price History

DVAX Company Calendar

Last Earnings
11/04/2021
Today
6/03/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:DVAX
CUSIP
26815810
Employees
311
Year Founded
1996

Price Target and Rating

Average Stock Price Forecast
$24.00
High Stock Price Forecast
$27.00
Low Stock Price Forecast
$21.00
Forecasted Upside/Downside
+105.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$293.16 million
Pretax Margin
36.26%

Debt

Sales & Book Value

Annual Sales
$722.68 million
Cash Flow
$2.36 per share
Book Value
$4.41 per share

Miscellaneous

Free Float
124,354,000
Market Cap
$1.49 billion
Optionable
Optionable
Beta
1.49

Social Links


Key Executives

  • Ryan SpencerRyan Spencer
    Chief Executive Officer & Director
  • David F. NovackDavid F. Novack
    President & Chief Operating Officer
  • Kelly MacDonaldKelly MacDonald
    Chief Financial Officer & Senior Vice President
  • Robert JanssenRobert Janssen
    Chief Medical Officer & SVP-Clinical Development
  • Todd Lopeman
    Vice President-Technical Operations













DVAX Stock - Frequently Asked Questions

Should I buy or sell Dynavax Technologies stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Dynavax Technologies in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DVAX shares.
View DVAX analyst ratings
or view top-rated stocks.

What is Dynavax Technologies' stock price forecast for 2023?

3 Wall Street research analysts have issued 12 month price objectives for Dynavax Technologies' stock. Their DVAX share price forecasts range from $21.00 to $27.00. On average, they expect the company's share price to reach $24.00 in the next year. This suggests a possible upside of 105.8% from the stock's current price.
View analysts price targets for DVAX
or view top-rated stocks among Wall Street analysts.

How have DVAX shares performed in 2023?

Dynavax Technologies' stock was trading at $10.64 at the start of the year. Since then, DVAX shares have increased by 9.6% and is now trading at $11.66.
View the best growth stocks for 2023 here
.

When is Dynavax Technologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our DVAX earnings forecast
.

How were Dynavax Technologies' earnings last quarter?

Dynavax Technologies Co. (NASDAQ:DVAX) posted its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the consensus estimate of $0.05 by $0.29. The biopharmaceutical company earned $108.27 million during the quarter, compared to analyst estimates of $77.30 million. Dynavax Technologies had a trailing twelve-month return on equity of 45.49% and a net margin of 35.99%. During the same period last year, the business earned ($0.15) EPS.

What is Eddie Gray's approval rating as Dynavax Technologies' CEO?

13 employees have rated Dynavax Technologies Chief Executive Officer Eddie Gray on Glassdoor.com. Eddie Gray has an approval rating of 59% among the company's employees. This puts Eddie Gray in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 61.0% of employees surveyed would recommend working at Dynavax Technologies to a friend.

What other stocks do shareholders of Dynavax Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dynavax Technologies investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (bmrn), (MDVN) (MDVN), Incyte (incy), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Matinas BioPharma (MTNB), First Solar (FSLR), Inovio Pharmaceuticals (INO) and ADMA Biologics (ADMA).

What is Dynavax Technologies' stock symbol?

Dynavax Technologies trades on the NASDAQ under the ticker symbol "DVAX."

Who are Dynavax Technologies' major shareholders?

Dynavax Technologies' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (14.78%), Federated Hermes Inc. (9.85%), State Street Corp (7.00%), Chicago Capital LLC (4.55%), Bank of America Corp DE (3.40%) and Fisher Asset Management LLC (3.09%). Insiders that own company stock include Andrew A F Hack, David F Novack, David F Novack, Francis Cano, Justin Burgess, Robert Janssen and Ryan Spencer.
View institutional ownership trends
.

How do I buy shares of Dynavax Technologies?

Shares of DVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Dynavax Technologies' stock price today?

One share of DVAX stock can currently be purchased for approximately $11.66.

How much money does Dynavax Technologies make?

Dynavax Technologies (NASDAQ:DVAX) has a market capitalization of $1.49 billion and generates $722.68 million in revenue each year. The biopharmaceutical company earns $293.16 million in net income (profit) each year or $1.56 on an earnings per share basis.

How many employees does Dynavax Technologies have?

The company employs 311 workers across the globe.

How can I contact Dynavax Technologies?

Dynavax Technologies' mailing address is 2100 Powell Street Suite 900, Emeryville CA, 94608. The official website for the company is www.dynavax.com. The biopharmaceutical company can be reached via phone at (510) 848-5100, via email at ir@dynavax.com, or via fax at 510-848-1327.

This page (NASDAQ:DVAX) was last updated on 6/4/2023 by MarketBeat.com Staff

My Account -